0.42
+2.93%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Novacyt
Its shares trade on Euronext Paris under the ticker ALNOV.PA. It has been listed since 12 October 2012. In the fiscal year to 31 December 2025, it reported revenue of £20.4m and a net loss of £23.3m. At that date it held total assets of £40.3m and shareholders' equity of £23.3m.
Novacyt SAS engages in the development and sale of cancer and infectious disease diagnostic products. The company is headquartered in Velizy-Villacoublay, Ile-De-France. The company went IPO on 2012-10-12. The firm develops and markets solutions dedicated to the field of liquid-based cytology and molecular biology. The firm provides diagnostic products used in oncology, microbiology, haematology, and serology testing. The firm develops secure automated cytology named NovaPrep Processor System. Novacyt SA offers a solution of cytological sampling to help in the detection of precancerous and cancerous lesions. The firm creates bottles specifically dedicated to the optimization of cell collection. The Company’s range of products includes Bottle Gyn and No Gyn Bottle. Novacyt SA is present in France and internationally through a network of distributors.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 12 Oct 2012
- Employees
- 119
- Website
- novacyt.com ↗
Leadership
Pay as last reported
- Dr. John BrownNon-Executive Chairman of the Board, since 2023£15,242
- Mr. Lyn ReesChief Executive Officer, Executive Director, since 2023£108,008
- Mr. Steve GibsonChief Financial Officer, Company Secretary, Director
- Mr. Peter CoyneChief Operating Officer
- Dr. Joanne MasonChief Scientific Officer, Executive Director, since 2024
- Ms. Wendy CoxDirector - Human Resources
- Ms. Maria WattersChief Commercial Officer
- Dr. Ian GilhamNon-Executive Director
- Mr. Jean-Pierre CrinelliIndependent Non-Executive Director, since 2021£34,037
- Ms. Juliet ThompsonIndependent Non-Executive Director£48,925
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Novacyt SA has a strong global presence, with operations in several countries and a diverse customer base.
- The company has a strong brand reputation and a track record of developing high-quality diagnostic products.
- Novacyt SA has a skilled and experienced workforce, which enables it to innovate and adapt quickly to changing market dynamics.
Weaknesses
- One of the weaknesses of Novacyt SA is its dependence on a few key customers, which exposes it to the risk of losing significant revenue if any of those customers switch to competitors.
- The company may face challenges in maintaining regulatory compliance across different markets due to variations in regulations.
- Novacyt SA operates in a highly competitive industry, which can put pressure on pricing and profit margins.
Opportunities
- There is a growing demand for diagnostic products and services globally, presenting an opportunity for Novacyt SA to expand its market share.
- The company can explore strategic partnerships or acquisitions to enhance its product portfolio and reach new markets.
- Advancements in technology and increasing awareness of preventive healthcare can create opportunities for Novacyt SA to develop innovative diagnostic solutions.
Threats
- The COVID-19 pandemic has resulted in increased competition in the diagnostic testing market, which can pose a threat to Novacyt SA's market position.
- Supply chain disruptions or shortages of raw materials can impact the company's production and delivery capabilities.
- Changes in healthcare policies or reimbursement rates can affect the demand and pricing of Novacyt SA's products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.